What is Neurocrine Biosciences, Inc.'s Shariah compliance score?

Neurocrine Biosciences, Inc. (NBIX) has a Shariah compliance score of 74/100 (Grade: B+, Good) based on AAOIFI screening standards. Scores above 70 typically indicate strong compliance. The score factors in business activity screening and financial ratio analysis including debt levels, interest-bearing deposits, and prohibited income percentages. View the full breakdown at HalalScreener.app.

Does Neurocrine Biosciences, Inc. pass AAOIFI screening?

Neurocrine Biosciences, Inc. (NBIX) passes AAOIFI Shariah screening. AAOIFI requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30% (NBIX: 2.4%), (3) interest-bearing deposits below 30% (NBIX: 5.6%), and (4) prohibited income below 5% (NBIX: 3.9%). HalalScreener provides free AAOIFI screening for 10,000+ stocks at halalscreener.app.

How much purification is needed for Neurocrine Biosciences, Inc. stock?

Neurocrine Biosciences, Inc. (NBIX) has a non-permissible income ratio of 3.94%. Muslim investors should purify this percentage of any dividends received and capital gains realized from NBIX shares by donating it to charity. HalalScreener's purification calculator at halalscreener.app/en/purification automates this calculation using the latest financial data.

Where can I screen Neurocrine Biosciences, Inc. for Shariah compliance for free?

HalalScreener (halalscreener.app) offers free Shariah compliance screening for Neurocrine Biosciences, Inc. (NBIX) and 10,000+ other US-listed stocks, ETFs, and 100+ cryptocurrencies. The screening uses AAOIFI Standard No. 21 and shows all financial ratios transparently. No credit card or signup required for basic screening. HalalScreener also includes an AI Islamic Scholar for follow-up questions about NBIX's compliance across different madhabs (Hanafi, Shafi'i, Maliki, Hanbali, Ja'fari).

NBIX: Is Neurocrine Biosciences, Inc. Halal?

Neurocrine Biosciences, Inc.

NASDAQHealthcareUS

$172.04

-1.18%

Market Cap: 17.3B

Compliance Status

Halal

Screened on Jul 15, 2026 · AAOIFI Standard 21

B+

Good

74Score

Is Neurocrine Biosciences, Inc. (NBIX) halal? Halal. Based on AAOIFI screening, Neurocrine Biosciences, Inc. passes both qualitative (business activity) and quantitative (financial ratio) screens with a compliance score of 74/100 (Grade: B+).

AvoidBorderlineClean

Business activity

What the company sells is permissible.

Passed

Company debt

Well clear of the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

2.4% of 30.0% limit

What this means for you

You can own NBIX

It passes both the business activity and financial ratio screens under AAOIFI Standard 21.

Purify 3.9% of your income from NBIX

That is about $3.90 of every $100 you earn from it. Donate this share to charity.

Calculate my exact amount

About Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.

Sector: Healthcare · Industry: Biotechnology

Shariah Compliance Status

AAOIFI Standard 21Updated Jul 15, 2026

Compliance History

Halalnow
since Jun 2026
Not Halal
until the change above
Halal
until the change above

Tracked since May 2026. Updates automatically on each re-screen.

Fiscal: Q1 2026Data source: EDGAR

More Healthcare Stocks

JNJ

Johnson & Johnson

UNH

UnitedHealth Group Incorporated

B+

ABBV

AbbVie Inc.

PFE

Pfizer Inc.

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

B+

Free · No credit card required

Track NBIX and 10,000+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

Get Started Free Browse Screener

10,000+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Neurocrine Biosciences, Inc. (NBIX) halal to invest in?

Based on AAOIFI Standard 21 screening, Neurocrine Biosciences, Inc. (NBIX) is rated Halal with a compliance grade of B+ (Good). It passes both the business activity screen (no primary involvement in prohibited sectors) and the quantitative financial ratio screen (debt, interest deposits, and prohibited income all below AAOIFI thresholds).

Why did Neurocrine Biosciences, Inc. get a B+ compliance rating?

Neurocrine Biosciences, Inc. (NBIX) received a grade of B+ (Good) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 2.4% (limit 30%); interest-bearing deposits of 5.6% (limit 30%); prohibited income of 3.94% (limit 5%). The grade reflects the margin of safety across all three ratios relative to their thresholds.

What could change Neurocrine Biosciences, Inc.'s Shariah verdict?

Neurocrine Biosciences, Inc.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.

How often is Neurocrine Biosciences, Inc. re-screened for Shariah compliance?

Neurocrine Biosciences, Inc. (NBIX) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Jul 15, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.